FAE Overzicht aandelen
Faes Farma, S.A., onderzoekt, ontwikkelt, produceert en verkoopt farmaceutische producten, gezondheidsproducten en grondstoffen wereldwijd.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 2/6 |
Beloningen
Risicoanalyse
Faes Farma, S.A. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €3.58 |
| 52 Week Hoogtepunt | €3.83 |
| 52 Week Laag | €2.91 |
| Bèta | 0.52 |
| 11 maand verandering | -2.98% |
| 3 maanden verandering | 3.17% |
| 1 Jaar Verandering | 18.94% |
| 33 jaar verandering | 3.59% |
| 5 jaar verandering | -28.11% |
| Verandering sinds IPO | 253.09% |
Recent nieuws en updates
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Recent updates
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316
Dec 18Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316
Dec 04Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?
Nov 24Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly
May 03Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?
Sep 21Is Faes Farma (BME:FAE) A Risky Investment?
Aug 03Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth
Jun 17Is Faes Farma (BME:FAE) Using Too Much Debt?
Mar 27Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14
Dec 13Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17
Nov 29Is Faes Farma (BME:FAE) A Risky Investment?
Sep 21Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Faes Farma (BME:FAE) Using Too Much Debt?
May 01Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)
Apr 07Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?
Mar 22Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations
Mar 06Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment
Feb 22I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease
Jan 16Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly
Dec 08Rendement voor aandeelhouders
| FAE | ES Pharmaceuticals | ES Markt | |
|---|---|---|---|
| 7D | -0.8% | -2.0% | -0.6% |
| 1Y | 18.9% | 11.6% | 25.9% |
Rendement versus industrie: FAE exceeded the Spanish Pharmaceuticals industry which returned 11.6% over the past year.
Rendement versus markt: FAE underperformed the Spanish Market which returned 25.9% over the past year.
Prijsvolatiliteit
| FAE volatility | |
|---|---|
| FAE Average Weekly Movement | 2.0% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 2.9% |
| 10% most volatile stocks in ES Market | 5.2% |
| 10% least volatile stocks in ES Market | 0.6% |
Stabiele aandelenkoers: FAE has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatiliteit in de loop van de tijd: FAE's weekly volatility (2%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1933 | 1,762 | n/a | faesfarma.com |
Faes Farma, S.A., onderzoekt, ontwikkelt, produceert en verkoopt farmaceutische producten, gezondheidsproducten en grondstoffen wereldwijd. Het bedrijf opereert via de segmenten Farmaceutische Producten en Gezondheidszorgspecialiteiten; Diervoeding en Gezondheid; en Farmaceutische Grondstoffen. Het biedt producten voor verschillende therapeutische gebieden.
Faes Farma, S.A. Samenvatting
| FAE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €1.11b |
| Inkomsten(TTM) | €97.59m |
| Inkomsten(TTM) | €504.04m |
11.4x
Koers/Winstverhouding2.2x
P/S-verhoudingIs FAE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| FAE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €504.04m |
| Kosten van inkomsten | €169.88m |
| Brutowinst | €334.16m |
| Overige uitgaven | €236.57m |
| Inkomsten | €97.59m |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.31 |
| Brutomarge | 66.30% |
| Nettowinstmarge | 19.36% |
| Schuld/Eigen Vermogen Verhouding | 6.9% |
Hoe presteerde FAE op de lange termijn?
Bekijk historische prestaties en vergelijking